ACELYRIN, Inc.

About ACELYRIN, Inc.

Acelyrin, Inc. is a late-stage clinical biopharma company focused on developing transformative medicines, particularly for autoimmune diseases. Its lead product, lonigutamab, targets Thyroid Eye Disease (TED) and aims to improve patient outcomes with subcutaneous delivery. With a significant market opportunity, Acelyrin is prioritizing lonigutamab while restructuring its pipeline. The company is also navigating a merger with Alumis to enhance its development capabilities and resources.